Karyopharm Therapeutics Inc.
General ticker "KPTI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $156.3M (TTM average)
Karyopharm Therapeutics Inc. does not follow the US Stock Market performance with the rate: -18.0%.
Estimated limits based on current volatility of 13.8%: low 0.34$, high 0.45$
Factors to consider:
- Total employees count: 228 (-18.3%) as of 2025
- Top business risk factors: Commercialization failure, Capital access, Regulatory and compliance, Intellectual property risks, Liquidity and credit risks
- Current price 91.2% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.43$, 14.84$]
- 2026-12-31 to 2027-12-31 estimated range: [2.60$, 9.40$]
Financial Metrics affecting the KPTI estimates:
- Negative: with PPE of -0.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -270.19 <= 7.04
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 53.78 > 2.08
Short-term KPTI quotes
Long-term KPTI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $146.03MM | $145.24MM | $146.07MM |
| Operating Expenses | $275.57MM | $264.68MM | $236.77MM |
| Operating Income | $-129.54MM | $-119.44MM | $-90.71MM |
| Non-Operating Income | $-13.24MM | $43.08MM | $-105.29MM |
| Interest Expense | $23.82MM | $37.42MM | $45.85MM |
| R&D Expense | $138.75MM | $143.23MM | $125.62MM |
| Income(Loss) | $-142.78MM | $-76.36MM | $-196.00MM |
| Taxes | $0.32MM | $0.06MM | $0.04MM |
| Net Income(Loss)* | $-143.10MM | $-76.42MM | $-196.04MM |
| Stockholders Equity | $-136.21MM | $-186.02MM | $-292.93MM |
| Inventory | $3.04MM | $4.74MM | $4.04MM |
| Assets | $240.44MM | $164.42MM | $108.42MM |
| Operating Cash Flow | $-92.72MM | $-127.49MM | $-75.37MM |
| Capital expenditure | $0.00MM | $0.14MM | $0.00MM |
| Investing Cash Flow | $7.94MM | $95.47MM | $43.38MM |
| Financing Cash Flow | $1.12MM | $41.65MM | $30.05MM |
| Earnings Per Share** | $-18.79 | $-9.41 | $-17.93 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.